BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

382 related articles for article (PubMed ID: 12764380)

  • 21. [Analysis of 21 children with acute non-lymphoid leukemia carrying AML1/ETO fusion gene].
    Zhao W; Li ZG; Wu MY; Geng LZ; Shi HW; Zhang YH; Wu RH
    Zhonghua Er Ke Za Zhi; 2003 May; 41(5):325-8. PubMed ID: 14751048
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Significance of quantification of WT1 mRNA for monitoring minimal residual disease in acute myeloid leukemia patients].
    Qin YZ; Ruan GR; Li JL; Fu JY; Chang Y; Wang H; Li LD; Liu YR; Chen SS
    Zhonghua Xue Ye Xue Za Zhi; 2005 Nov; 26(11):649-52. PubMed ID: 16620548
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Complex translocation (8;12;21): a new variant of t(8;21) in acute myeloid leukemia.
    Farra C; Awwad J; Valent A; Lozach F; Bernheim A
    Cancer Genet Cytogenet; 2004 Dec; 155(2):138-42. PubMed ID: 15571799
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fusion gene transcripts and Ig/TCR gene rearrangements are complementary but infrequent targets for PCR-based detection of minimal residual disease in acute myeloid leukemia.
    Boeckx N; Willemse MJ; Szczepanski T; van der Velden VH; Langerak AW; Vandekerckhove P; van Dongen JJ
    Leukemia; 2002 Mar; 16(3):368-75. PubMed ID: 11896540
    [TBL] [Abstract][Full Text] [Related]  

  • 25. AML1-ETO positive AML: first report from India.
    Dutta P; Hasan SK; Sazawal S; Kumar B; Bhattacharyya J; Jain M; Tyagi S; Kumar R; Pati HP; Saxena R
    Indian J Pathol Microbiol; 2007 Jul; 50(3):652-4. PubMed ID: 17883173
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessment of minimal residual disease (MRD) in CBFbeta/MYH11-positive acute myeloid leukemias by qualitative and quantitative RT-PCR amplification of fusion transcripts.
    Guerrasio A; Pilatrino C; De Micheli D; Cilloni D; Serra A; Gottardi E; Parziale A; Marmont F; Diverio D; Divona M; Lo Coco F; Saglio G
    Leukemia; 2002 Jun; 16(6):1176-81. PubMed ID: 12040450
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High expression of c-kit mRNA predicts unfavorable outcome in adult patients with t(8;21) acute myeloid leukemia.
    Gao X; Lin J; Gao L; Deng A; Lu X; Li Y; Wang L; Yu L
    PLoS One; 2015; 10(4):e0124241. PubMed ID: 25860287
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic value of AML 1/ETO fusion transcripts in patients with acute myelogenous leukemia.
    Cho EK; Bang SM; Ahn JY; Yoo SM; Park PW; Seo YH; Shin DB; Lee JH
    Korean J Intern Med; 2003 Mar; 18(1):13-20. PubMed ID: 12760263
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular quantification of response to therapy and remission status in TEL-AML1-positive childhood ALL by real-time reverse transcription polymerase chain reaction.
    Seeger K; Kreuzer KA; Lass U; Taube T; Buchwald D; Eckert C; Körner G; Schmidt CA; Henze G
    Cancer Res; 2001 Mar; 61(6):2517-22. PubMed ID: 11289124
    [TBL] [Abstract][Full Text] [Related]  

  • 30. AML1-ETO9a is correlated with C-KIT overexpression/mutations and indicates poor disease outcome in t(8;21) acute myeloid leukemia-M2.
    Jiao B; Wu CF; Liang Y; Chen HM; Xiong SM; Chen B; Shi JY; Wang YY; Wang JH; Chen Y; Li JM; Gu LJ; Tang JY; Shen ZX; Gu BW; Zhao WL; Chen Z; Chen SJ
    Leukemia; 2009 Sep; 23(9):1598-604. PubMed ID: 19458628
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High WT1 expression after induction therapy predicts high risk of relapse and death in pediatric acute myeloid leukemia.
    Lapillonne H; Renneville A; Auvrignon A; Flamant C; Blaise A; Perot C; Lai JL; Ballerini P; Mazingue F; Fasola S; Dehée A; Bellman F; Adam M; Labopin M; Douay L; Leverger G; Preudhomme C; Landman-Parker J
    J Clin Oncol; 2006 Apr; 24(10):1507-15. PubMed ID: 16575000
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pre-clinical evaluation of probes to detect t(8;21) AML minimal residual disease by fluorescence in situ hybridization.
    Paskulin GA; Philips G; Morgan R; Sandberg A; Richkind K; Borovik C; McGavran L; Rabinovich N; Dietz-Band J; Erickson P; Drabkin H; Varella-Garcia M
    Genes Chromosomes Cancer; 1998 Feb; 21(2):144-51. PubMed ID: 9491326
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serial quantification of minimal residual disease of t(8;21) acute myelogenous leukaemia with RT-competitive PCR assay.
    Muto A; Mori S; Matsushita H; Awaya N; Ueno H; Takayama N; Okamoto S; Kizaki M; Ikeda Y
    Br J Haematol; 1996 Oct; 95(1):85-94. PubMed ID: 8857943
    [TBL] [Abstract][Full Text] [Related]  

  • 34. AML1-ETO downregulates the granulocytic differentiation factor C/EBPalpha in t(8;21) myeloid leukemia.
    Pabst T; Mueller BU; Harakawa N; Schoch C; Haferlach T; Behre G; Hiddemann W; Zhang DE; Tenen DG
    Nat Med; 2001 Apr; 7(4):444-51. PubMed ID: 11283671
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic significance of the AML1-ETO fusion transcript expression in children and young adults with t(8;21) acute myeloid leukemia.
    Fleischman EW; Baturina JA; Sokova OI; Popa AV; Kosorukova IS; Rowley JD
    Haematologica; 2003 Sep; 88(9):1078-9. PubMed ID: 12969821
    [No Abstract]   [Full Text] [Related]  

  • 36. The quality of molecular response to chemotherapy is predictive for the outcome of AML1-ETO-positive AML and is independent of pretreatment risk factors.
    Weisser M; Haferlach C; Hiddemann W; Schnittger S
    Leukemia; 2007 Jun; 21(6):1177-82. PubMed ID: 17377588
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Quantitative RT-PCR analysis of the MOZ-CBP fusion transcript in therapy-related acute myeloid leukemia with t(8;16)(p11;p13).
    Fujiki A; Imamura T; Furutani A; Hatano W; Asai D; Hirashima Y; Miyachi M; Tamura S; Tsuchiya K; Iehara T; Ishida H; Yoshihara T; Hosoi H
    J Pediatr Hematol Oncol; 2012 Jul; 34(5):402-5. PubMed ID: 22278196
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Persistence of multipotent progenitors expressing AML1/ETO transcripts in long-term remission patients with t(8;21) acute myelogenous leukemia.
    Miyamoto T; Nagafuji K; Akashi K; Harada M; Kyo T; Akashi T; Takenaka K; Mizuno S; Gondo H; Okamura T; Dohy H; Niho Y
    Blood; 1996 Jun; 87(11):4789-96. PubMed ID: 8639850
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Preclinical validation of a monochrome real-time multiplex assay for translocations in childhood acute lymphoblastic leukemia.
    Siraj AK; Ozbek U; Sazawal S; Sirma S; Timson G; Al-Nasser A; Bhargava M; El Solh H; Bhatia K; Gutiérrez MI
    Clin Cancer Res; 2002 Dec; 8(12):3832-40. PubMed ID: 12473597
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Monitoring of fusion gene transcripts to predict relapse in pediatric acute myeloid leukemia.
    Matsuo H; Iijima-Yamashita Y; Yamada M; Deguchi T; Kiyokawa N; Shimada A; Tawa A; Tomizawa D; Taga T; Kinoshita A; Adachi S; Horibe K
    Pediatr Int; 2018 Jan; 60(1):41-46. PubMed ID: 29067751
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.